Drug pricing matters, but pipelines matter even more.
The tables have turned for the U.S. biosimilars market. With more than a decade since the first FDA biosim approval, strong launches to biologic copies to AbbVie’s Humira, J&J’s Stelara and ...
In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more.
NHS England has spent £13bn on the most expensive treatments in the past 10 years with the drugs companies making up to £12.6bn through 'extreme profiteering', according to health campaign groups ...
AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See more on ABBV here.
When British Prime Minister Keir Starmer led the Labour Party to a landslide victory in July 2024, he hailed the result as the end of 14 years of misrule by the Conservative Party and the beginning of ...
The president has executed nearly 400 healthcare trades this year. See how the top 10 most-traded names are performing and what's driving them.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results